Clinical trial
A Phase 1 Single and Multiple Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Immunogenicity of HuL001 in Healthy Volunteers and Idiopathic Pulmonary Fibrosis Subjects
NCT04540770 is registered in ClinicalTrials.gov with HuniLife Biotechnology, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1 Single and Multiple Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Immunogenicity of HuL001 in Healthy Volunteers and Idiopathic Pulmonary Fibrosis Subjects
- Lead sponsor
- HuniLife Biotechnology, Inc.
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- August 31, 2021
- Completion date
- January 19, 2024
- Enrollment
- 24 (actual)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.